Chronic Leukemia

Chronic leukemia is a long term increase of abnormal white blood cells. It can be classed as myelogenous or lymphocytic leukemia. For more information see the Leukemia pages Add the Leukemia New...

Acute Leukemia

Acute leukemia occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity. These lymphocytes (acute lymphocytic leukemia...

Acute Myelocytic Leukemia AML

Acute myelocytic leukemia is a life-threatening disease in which the neutrophil, basophil, eosinophil, and monocyte precursors become cancerous and rapidly replace normal cells in the bone marrow....

Acute Lymphocytic Leukemia ALL

Acute lymphocytic leukemia (ALL) is a life-threatening disease in which the cells that normally develop into lymphocytes become cancerous and rapidly replace normal cells in the bone marrow. ALL acc...

Chronic Myelocytic Leukemia CML

Chronic myelocytic leukemia is the resulting disease when neutrophil, basophil, eosinophil, and monocyte progenitors become cancerous. It is usually caused by the presence of the Philadelphia chromo...

Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia

Rare leukemia-causing protein discovered

Researchers have discovered a new gene target for leukemia therapy. Researchers found that by inhibiting in animal models the protein Vav3, which controls cell signaling, the development of this leuke...

Alison Ryan, SGI's Global Channel Sales Vice President, Recognized as one of UBM Tech Channel's CRN 2013 Channel Chiefs

FREMONT, Calif., Feb. 27, 2013 (GLOBE NEWSWIRE) -- SGI (Nasdaq:SGI), the trusted leader in technical computing, announced today that Alison Ryan has been named one of UBM Tech Channel's CRN 2013 Ch...

Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months

Ponatinib received accelerated approval for use in chronic myeloid leukemia and acute lymphoblastic leukemia patients who are resistant or intolerant to prior therapy with tyrosine kinase inhibitors.

Ariad Pharma files for approval of leukemia drug

Ariad Pharmaceuticals Inc. said Monday it filed for U.S. marketing approval of leukemia drug ponatinib.Ariad said it asked the Food and Drug Administration to approve ponatinib as a treatment for chr...

One ion channel, many diseases

A dysfunction of a certain Calcium channel, the so called P/Q-type channel, in neurons of the cerebellum is sufficient to cause different motor diseases as well as a special type of epilepsy. This is...

Chernobyl and Leukemia Risk

Workers involved in recovery and cleanup at the Chernobyl nuclear power plant that exploded in 1986 in the former Soviet territory of Ukraine have an elevated risk of chronic lymphocytic leukemia (CLL...

Japan Researchers Destroy Adult Leukemia Stem Cells In Animal Trial

Japan scientists report success in destroying stem cells believed responsible for an adult type of leukemia, acute myelogenous leukemia.

Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia.

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.

Kv3.4 potassium channel-mediated electrosignaling controls cell cycle and survival of irradiated leukemia cells.

Aberrant ion channel expression in the plasma membrane is characteristic for many tumor entities and has been attributed to neoplastic transformation, tumor progression, metastasis, and therapy resist...

The t(4;9)(q11;q33) fuses CEP110 to KIT in a case of acute myeloid leukemia.